Daratumumab for POEMS Syndrome

Mayo Clin Proc. 2018 Apr;93(4):542-544. doi: 10.1016/j.mayocp.2018.02.001.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antineoplastic Agents / administration & dosage*
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Female
  • Humans
  • Immunologic Factors / administration & dosage
  • Lenalidomide / administration & dosage
  • Middle Aged
  • POEMS Syndrome / blood
  • POEMS Syndrome / drug therapy*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunologic Factors
  • daratumumab
  • Lenalidomide